SELPLG and Miyoshi myopathy: We find that targeting the BMME with PSGL-1-targeted BTZ and ROCK inhibitor-loaded liposomes is more effective than free drugs, non-targeted liposomes, and single-agent controls, and reduces BTZ-associated side effects, for the treatment of MM.